In the SORAMIC trial, Öcal et al. demonstrated that baseline IL-6 and IL-8 levels predict the response to sorafenib as well as predict overall survival, supporting the role of IL-8 as a potentially predictive biomarker for optimizing treatment in hepatocellular carcinoma [70]. The gene discussed is CXCL8; the disease is hepatocellular carcinoma.